Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Icosavax, Inc. in the transaction. Icosavax, Inc. closed a US$100 million Series B Financing, led by RA Capital Management and joined by...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, completed a US$40...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Longboard Pharmaceuticals, Inc. closed its initial public offering of 5 million shares of its common stock at...
You must be a Standard 1 Year member to access this content.
